United States - English - NLM (National Library of Medicine)

almay, inc. - salicylic acid (unii: o414pz4lpz) (salicylic acid - unii:o414pz4lpz) - salicylic acid 0.5 mg in 1 ml - anti acne •helps clear and prevent blemishes

United States - English - NLM (National Library of Medicine)

almay, inc. - titanium dioxide (unii: 15fix9v2jp) (titanium dioxide - unii:15fix9v2jp), zinc oxide (unii: soi2loh54z) (zinc cation - unii:13s1s8sf37) - titanium dioxide 4.7 mg in 1 ml - sunscreen •helps prevent sunburn •if used as directed with other sun protection measures (see directions), decreases the risk of skin cancer and early skin aging caused by the sun

United States - English - NLM (National Library of Medicine)

almay, inc. - zinc oxide (unii: soi2loh54z) (zinc cation - unii:13s1s8sf37), titanium dioxide (unii: 15fix9v2jp) (titanium dioxide - unii:15fix9v2jp) - zinc cation 2 mg in 1 ml - sunscreen •helps prevent sunburn •if used as directed with other sun protection measures (see directions), decreases the risk of skin cancer and early skin aging caused by the sun

United States - English - NLM (National Library of Medicine)

almay, inc. - salicylic acid 2.0% - - for the treatment/management of acne. - • helps clear and prevent new acne blemishes. helps clear and prevent new acne blemishes

United States - English - NLM (National Library of Medicine)

almay - homosalate (unii: v06sv4m95s) (homosalate - unii:v06sv4m95s), octisalate (unii: 4x49y0596w) (octisalate - unii:4x49y0596w), zinc oxide (unii: soi2loh54z) (zinc oxide - unii:soi2loh54z), octocrylene (unii: 5a68wgf6wm) (octocrylene - unii:5a68wgf6wm), titanium dioxide (unii: 15fix9v2jp) (titanium dioxide - unii:15fix9v2jp) - helps prevent sunburn. if used as directed with other sun protection measures descreases the risk of skin cancer and early skin aging caused by the sun.

United States - English - NLM (National Library of Medicine)

almay - salicylic acid (unii: o414pz4lpz) (salicylic acid - unii:o414pz4lpz) - helps clear and prevent new acne blemishes anti-acne treatment

United States - English - NLM (National Library of Medicine)

almay - salicylic acid (unii: o414pz4lpz) (salicylic acid - unii:o414pz4lpz) - acne treatment helps clear and prevent new acne blemishes

United States - English - NLM (National Library of Medicine)

chc montana - lycoperdon utriforme fruiting body (unii: k2a74u428f) (lycoperdon utriforme fruiting body - unii:k2a74u428f), claviceps purpurea sclerotium (unii: 01g9xea93n) (claviceps purpurea sclerotium - unii:01g9xea93n), ustilago maydis (unii: 4k7z7k7swg) (ustilago maydis - unii:4k7z7k7swg), wyethia helenioides root (unii: j10pd1aq0n) (wyethia helenioides root - unii:j10pd1aq0n) - bovista lycoperdon 30c..........................dullness, stuffy head secale cornutum 6c..........mold & hay irritation eyes & nose ustilago maydis 12c................sticky eye, bloody discharges wyethia helenioides 12c..........................itchy throat & mouth mold, dust & hay spritz helpful for relief of allergy symptoms - sneezing, itching, dullness, stuffy head, runny eyes & sinuses.

Australia - English - Department of Health (Therapeutic Goods Administration)

mayne pharma international pty ltd - erythromycin, quantity: 250 mg - capsule, enteric - excipient ingredients: gelatin; povidone; cellacefate; lactose monohydrate; monobasic potassium phosphate; diethyl phthalate; erythrosine; indigo carmine; carbon black; purified water; shellac; sunset yellow fcf - indications as at 22 may 2003: eryc is indicated in children and adults for the treatment of the following conditions: upper respiratory tract infections of mild to moderate degree caused by streptococcus pyogenes (group a beta haemolytic streptococci), streptococcus pneumoniae (diplococcus pneumoniae). lower respiratory tract infections of mild to moderate severity caused by streptococcus pyogenes (group a beta hemolytic streptococci), streptococcus pneumoniae (diplococcus pneumoniae), acute and chronic bronchitis, pneumonia. sinusitis caused by streptococcus pneumoniae, streptococcus pyogenes. otitis media due to streptococcus pneumoniae, streptococcus pyogenes. respiratory tract infections due to mycoplasma pneumonia (eaton's agent). skin, and skin structure infections of mild to moderate severity caused by streptococcus pyogenes and staphylococcus aureus (resistant staphylococci may emerge during treatment). bordetella pertussis: erythromycin produces early elimination of the causative organism from the nasopharynx although the clinical course of the disease is not altered; therapeutic doses should be continued for at least 10 days. diphtheria: as an adjunct to antitoxin infections due to corynebacterium diphtheriae, to prevent establishment of carriers and to eradicate the organism in carriers. erythrasma: in the treatment of infections due to corynebacterium minutissimum. non-gonococcal urethritis: chlamydia trachomatis and ureaplasma urealyticum have been shown to be sensitive to erythromycin and clinical studies have demonstrated its efficacy in urethritis due to these organisms. a minimum of 10 days therapy appears to be required. chlamydia trachomatis infection (excluding non-gonococcal urethritis): erythromycin has been shown to be effective in the treatment of trachoma or inclusion-body conjunctivitis and pneumonia in infants caused by chlamydia trachomatis. campylobacter fetus (subspecies) jejuni: infections due to this organism when antibiotic therapy is indicated. primary syphilis caused by treponema pallidum: erythromycin (oral forms only) is an alternative choice of treatment for primary syphilis in patients allergic to the penicillins. in the treatment of primary syphilis, spinal fluid should be examined before treatment and as part of the followup after therapy. legionnaires' disease caused by legionella pneumophila: although no controlled clinical efficacy studies have been conducted, in vitro and limited preliminary clinical data suggest that erythromycin may be effective in treating legionnaires' disease. prevention of initial attacks of rheumatic fever: penicillin is considered by the american heart association to be the drug of choice in the prevention of initial attacks of rheumatic fever (treatment of group a beta - haemolytic streptococcal infections of the upper respiratory tract e.g. tonsillitis or pharyngitis). erythromycin is indicated for the treatment of penicillin allergic patients. a therapeutic dose should be administered for 10 days. prevention of recurrent attacks of rheumatic fever: penicillin or sulphonamides are considered by the american heart association to be the drugs of choice in the prevention of recurrent attacks of rheumatic fever. in patients who are allergic to penicillin and sulphonamides, oral erythromycin is recommended by the american heart association in the long term prophylaxis of streptococcal pharyngitis (for the prevention of recurrent attacks of rheumatic fever). prevention of bacterial endocarditis: although no controlled clinical efficacy trials have been conducted, oral erythromycin has been suggested by the american heart association and the american dental association in a regimen for prophylaxis against bacterial endocarditis in patients sensitive to penicillin who have congenital heart disease, or rheumatic or other acquired valvular heart disease when they undergo dental or surgical procedures of the upper respiratory tract. erythromycin is n ot suitable prior to genitourinary or gastrointestinal tract surgery.

Australia - English - Department of Health (Therapeutic Goods Administration)

mayne pharma international pty ltd - doxycycline hyclate, quantity: 116.3 mg (equivalent: doxycycline, qty 100 mg) - capsule, modified release - excipient ingredients: microcrystalline cellulose; lactose monohydrate; magnesium stearate; purified water; hypromellose phthalate; hyprolose; wheat starch; diethyl phthalate; hypromellose; gelatin; povidone; ethanol; shellac; pharmaceutical glaze; carbon black - indications as at 24 march 2004: doxycycline is primarily bacteriostatic and is thought to exert its antimicrobial effect by the inhibition of protein synthesis. doxycycline is active against a wide range of gram positive and gram negative organisms. note: the 50 mg capsule is not a paediatric formulation. doryx is indicated in the treatment of infections caused by the following micro-organisms: mycoplasma pneumoniae: primary atypical pneumonia. rickettsiae: queensland tick typhus, typhus fever and q fever agents of psittacosis. calymmatobacterium (donovania) granulomitis: granuloma inguinale. agents of lymphogranuloma venereum. borreliae: relapsing fever. chlamydia trachomatis. doryx is indicated in the treatment of trachoma, although the infectious agent is not always eliminated, as judged by immunofluorescence. inclusion conjunctivitis may be treated with oral doryx alone, or in combination with topical agents. doryx is indicated in the treatment of infections caused by the following gram negative micro-or